Xingfen Lang

Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.

Xiaoyun Lu, Zheng-chao Tu, Deping Wang, 2013, Journal of medicinal chemistry.

Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly

S. Waddell, L. Alderwick, J. Fossey, 2020, bioRxiv.

Design and biological evaluation of substituted 5,7-dihydro-6H-indolo[2,3-c]quinolin-6-one as novel selective Haspin inhibitors

P. Bonnet, S. Ruchaud, S. Routier, 2022, Journal of enzyme inhibition and medicinal chemistry.

Evaluation of aminohydantoins as a novel class of antimalarial agents.

D. Griggs, D. Goldberg, Xiaoyun Lu, 2014, ACS medicinal chemistry letters.